caa a22 4500 477056903 CHVBK 20180405111348.0 cr unu---uuuuu 170330e19960701xx s 000 0 eng 10.1007/s002280050140 doi (NATIONALLICENCE)springer-10.1007/s002280050140 Effect of N-acetylcysteine(NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial [Elektronische Daten] [B. Åkerlund, C. Jarstrand, B. Lindeke, A. Sönnerborg, A.-C. Åkerblad, O. Rasool] Objective: In a double-blind placebo-controlled trial, human immunodeficiency virus (HIV)-seropositive patients with a CD4 lymphocyte cell count of more than 200 × 106⋅l−1 were randomised to receive either 800 mg N-acetylcysteine (NAC) or placebo for 4 months. Before treatment low plasma cysteine levels, high free radical activity in neutrophils in the presence of autologous plasma - measured by the nitroblue tetrazolium (NBT) test - and increased tumor necrosis factor (TNF)-α levels were found in the HIV positive patients. Results: After treatment the low plasma cysteine level in the NAC group increased to normal, and the decline of the CD4+ lymphocyte count before the study start, was less steep in the NAC group than in the placebo group after treatment. There was also a reduction in TNF-α level. However, NAC had no effect on the radical production by neutrophils, and although it did not increase the CD4+ cell count, it may have decreased the decline in CD4+ cells. Conclusion: Further controlled trials with NAC are needed to devermine whether it has a beneficial effect in the treatment of asymptomatic HIV-infected individuals. Springer-Verlag Berlin Heidelberg, 1996 Key words N-acetylcysteine treatment nationallicence HIV-1 infection nationallicence oxidative stress nationallicence free radical generation nationallicence Åkerlund B. Department of Infectious Diseases, Karolinska Institute, Huddinge Hospital, S-141 86 Huddinge, Sweden, SE aut Jarstrand C. Department of Bacteriology, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden, SE aut Lindeke B. Swedish Academy of Pharmaceutical Science, Stockholm, Sweden, SE aut Sönnerborg A. Department of Virology, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden, SE aut Åkerblad A.-C Pfizer AB, Taby, Sweden, SE aut Rasool O. Department of Bacteriology, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden, SE aut https://doi.org/10.1007/s002280050140 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050140 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Åkerlund B. Department of Infectious Diseases, Karolinska Institute, Huddinge Hospital, S-141 86 Huddinge, Sweden, SE aut NATIONALLICENCE 700 1- Jarstrand C. Department of Bacteriology, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden, SE aut NATIONALLICENCE 700 1- Lindeke B. Swedish Academy of Pharmaceutical Science, Stockholm, Sweden, SE aut NATIONALLICENCE 700 1- Sönnerborg A. Department of Virology, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden, SE aut NATIONALLICENCE 700 1- Åkerblad A.-C Pfizer AB, Taby, Sweden, SE aut NATIONALLICENCE 700 1- Rasool O. Department of Bacteriology, Karolinska Institute, Huddinge Hospital, Huddinge, Sweden, SE aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer